Page 12 - Intern Med News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Guidance conflicts with other new recommendations that screening start at age 45

Donanemab has been hailed in the global media as a “turning point in the fight against Alzheimer’s disease” on the back of donanemab’s manufacturer releasing final results of the phase 3 Trailblazer Alz-2 trial simultaneously at a conference and in JAMA . The drug that is designed to break up amyloid-beta clumps (like lecanemab, which recently gained FDA approval) seemed to slow cognitive and functional decline by an average 36% and 40% over 18 months respectively in people with early Alzheimer’s disease whose brain scans showed low to medium levels of tau (the secondary abnormal pro...

Smoking cessation treatments seem to have gone out of fashion. I used to light up (with enthusiasm, not pull out a Zippo) when a smoker came to see me and reel off stats about the success rates of our in-house smoking cessation clinic. But when everyone decided it was fine to vape instead (remember the 95% less harmful stat?) the funding was cut, and now we can just direct people to the nearest vape store, petrol station, or sweet shop for their non-smoker nicotine fix. Maybe a new drug is what we need to reignite our smoking cessation efforts? Could cytisinicline, a plant based alkaloid, be ...

Changes in eGFR not significant when taking into account pre-hospitalization values

Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.